Affiliation:
1. Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
Abstract
:
Small interfering RNAs (siRNAs) have rapidly developed into biomedical research as a
novel tool for the potential treatment of various human diseases. They are based on altered gene expression.
In spite of the availability of highly active antiretroviral therapy (HAART), there is a specific
interest in developing siRNAs as a therapeutic agent for human immunodeficiency virus (HIV) due to
several problems including toxicity and drug resistance along with long term treatment. The successful
use of siRNAs for therapeutic goals needs safe and effective delivery to specific cells and tissues. Indeed,
the efficiency of gene silencing depends on the potency of the carrier used for siRNA delivery.
The combination of siRNA and nano-carriers is a potent method to prevent the limitations of siRNA
formulation. Three steps were involved in non-viral siRNA carriers such as the complex formation of
siRNA with a cationic carrier, conjugation of siRNA with small molecules, and encapsulation of siRNA
within nanoparticles.
:
In this mini-review, the designed siRNAs and their carriers are described against HIV-1 infections both
in vitro and in vivo.
Publisher
Bentham Science Publishers Ltd.
Subject
General Health Professions
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献